Dinglan Wu

8PUBLICATIONS
39CO-AUTHORS
Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cellular nervous systemCancer therapy (excl. chemotherapy and radiation therapy)Medical devices
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Oct 05, 2026
Targeting SLC38A5 Overcomes αPD-1 Immunotherapy Resistance by Alleviating Glutamine Competition Between Glioblastoma Cells and T Cells.

|Mar 03, 2026
GITR activation potentiates anti-tumor immunity of tumor-infiltrating lymphocytes expanded from glioblastoma by rescuing exhaustion.

Jiayi Zhou, Yinggui Yang, Ran Ye

|Oct 18, 2025
Neuroscience in prostate cancer.

Ziteng Liu, Qiang Peng, Yuliang Wang

|Sep 25, 2024
Nuclear receptor TLX functions to promote cancer stemness and EMT in prostate cancer via its direct transactivation of CD44 and stem cell-regulatory transcription factors.

Sin Ting Chow, Jiaqi Fan, Xingxing Zhang

|Apr 22, 2024
Interferon-induced transmembrane protein-1 competitively blocks Ephrin receptor A2-mediated Epstein-Barr virus entry into epithelial cells.

Yinggui Yang, Tengteng Ding, Ying Cong

|Jan 21, 2023
Alterations of plasma exosomal proteins and motabolies are associated with the progression of castration-resistant prostate cancer.

Pengyu Liu, Wenxuan Wang, Fei Wang

Pageof 2

Frequent Collaborators

3 joint publications

Chi-Fai Ng

2 joint publications

Zhuohao Liu

2 joint publications

Jie Mao

2 joint publications

Yinggui Yang